Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Ipsidy Announces Upcoming Investor Presentation and Conference Schedule


LONG BEACH, New York, March 8, 2018 /PRNewswire/ --

Ipsidy Inc. (www.ipsidy.com) (OTCQB : IDTY), a provider of secure, biometric identification, identity management and electronic transaction processing services, today announced it will attend the following conferences in March 2018:

Presenting at:

Craig-Hallum Capital Group's FinTech Innovators Conference
Thursday, March 15th at 2:30 pm ET
Panel Discussion: Future of Banking - Technology Innovations Drivers
Langham Hotel, Boston

Exhibiting at:

2018 KNOW Identity Conference
Hosted by One World Identity (OWI)
March 26-28, 2018
Ronald Reagan Building and International Trade Center
Washington, D.C.

The KNOW Identity Conference is the nexus for identity innovation, offering a differentiated, powerful, and immersive event convening the world's most influential organizations and smartest minds across industries to shape the future of identity.

About Ipsidy 

Ipsidy Inc (OTCQB: IDTY) www.ipsidy.com (formerly known as ID Global Solutions Corporation OTC:IDGS) is a provider of secure, biometric identification, identity management and electronic transaction processing services. Ipsidy is headquartered in New York and has operating subsidiaries: MultiPay in Colombia, www.multipay.com.co and Cards Plus in South Africa, www.cardsplus.co.za . Our identity transaction platform creates a trusted transaction, embedding authenticated identity and event details with a digital signature and using a participant's mobile device to approve everyday transactions. Our platform is being designed to use biometric and multi-factor identity management solutions, which are intended to support a wide variety of electronic transactions. We believe that it is essential that businesses and consumers know who is on the other side of an electronic transaction and have an audit trail, proving that the identity of the other party was duly authenticated. We continue to enhance our solutions to provide our customers with the next level of transaction security, control and certainty over everyday transactions. Further information on Ipsidy can be found at www.ipsidy.com or contact us at [email protected].

Contacts: 

Ipsidy Inc.
Philip D. Beck
Chairman, CEO & President 
+1(516)274-8700
[email protected]

SOURCE Ipsidy Inc.


These press releases may also interest you

at 07:05
Executive War College to Address, Clinical Laboratories' and Genetic Testing Firms' Perfect Storm, involving FDA's Proposed LDT Rule, Payers Requiring Z-Codes on Genetic Test Claims, and Revisions to CLIA Regulations
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
GLOBE LIFE INC. ANNOUNCES FIRST QUARTER 2024 EARNINGS RELEASE AND CONFERENCE CALL
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

at 07:00
Drug-Free Pain Relief Comes in the Form of Red Laser Therapy
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...

More news about Health...


News published on and distributed by: